Abstract 3944
Background
We initially ascertained the value of inflammatory indexes in predicting severe acute radiation pneumonitis (SARP). Furthermore, we firstly built a novel nomogram and risk classification system integrating clinicopathological, dosimetric and biological parameters to individually and precisely identify SARP in patients with esophageal cancer (EC) who received radiotherapy (RT).
Methods
All data were collected from 312 EC patients. Logistic regression was used to choose predictors of SARP and then build nomogram. The validation of nomogram was performed by area under the ROC curve (AUC), calibration curves and decision curve analyses (DCA). A risk classification system was generated by recursive partitioning analysis (RPA).
Results
The Subjective Global Assessment (SGA) score, pulmonary fibrosis score (PFS), planning target volume/total lungs volume (PTV/LV), mean lung dose (MLD) and systemic immuneinflammation index (SII) were independent predictors of SARP and finally incorporated into the nomogram. The AUC of nomogram for SARP prediction was 0.852, which was much higher than any other factor (range, 0.604-0.712). Calibration curves indicated favorable consistency between the nomogram prediction and the actual outcomes. DCA exhibited satisfactory clinical utility. A risk classification system was built to perfectly divide patients into three risk groups which were low-risk group (7.1%, score 0–158), intermediate-risk group (38%, score 159–280), and high-risk group (71.4%, score>280).
Conclusions
SGA score, PFS, PTV/LV, MLD and SII were potential valuable markers in predicting SARP. The constructed nomogram and corresponding risk classification system with superior prediction ability for SARP could assist in patients counseling and guide treatment decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3392 - Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: (a GINECO study)
Presenter: Skerdi HAVIARI
Session: Poster Display session 2
Resources:
Abstract
714 - The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian insufficiency in patient with malignant ovarian germ cell tumors
Presenter: Min Kyu Kim
Session: Poster Display session 2
Resources:
Abstract
1753 - Ex vivo cytotoxicity and in vivo antitumor activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer
Presenter: Kosei Hasegawa
Session: Poster Display session 2
Resources:
Abstract
3739 - Mutational landscapes and tumor mutational burden expression in endometrial cancer
Presenter: Yingli Zhang
Session: Poster Display session 2
Resources:
Abstract
2109 - Clinical features and frequency of mismatch repair protein deficiency in ovarian clear cell and endometrioid carcinoma patients.
Presenter: Kazuhiro Takehara
Session: Poster Display session 2
Resources:
Abstract
4554 - Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer
Presenter: Lea Moukarzel
Session: Poster Display session 2
Resources:
Abstract
3645 - Cancer-specific survival with or without adjuvant chemotherapy in high-risk stage I endometrial cancer
Presenter: Jenny Ko
Session: Poster Display session 2
Resources:
Abstract
3394 - Pembrolizumab in Patients with MSI-H Advanced Endometrial Cancer from the KEYNOTE-158 Study
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
3388 - Who drops out of cervical cancer screening? Results from the EDIFICE 6 survey
Presenter: Thibault de La Motte Rouge
Session: Poster Display session 2
Resources:
Abstract
2485 - Identification of a RNA-Seq Based Signature to Improve Prognostic for Uterine Sarcoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 2
Resources:
Abstract